Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 8/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.46 |
| ▸ | TDO2 | P48775 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730148 | 0.82 | MKNK1 (0.57) | FEN1ALOX5APTDO2MAP4K4PIK3CD | |
| SCHEMBL13750510 | 0.80 | DHODH (0.46) | TDO2CYP11B2MAPTMAOAMAOB | |
| SCHEMBL18255779 | 0.79 | CYP11B2 (0.47) | CYP11B2MAPTMAOAMAOBMAP4K4 | |
| SCHEMBL15638280 | 0.79 | PIK3CD (0.52) | FEN1ALOX5APMAP4K4PIK3CDMKNK1 | |
| SCHEMBL4017379 | 0.78 | FEN1 (0.67) | FEN1ALOX5APTDO2MAP4K4 | |
| SCHEMBL4023179 | 0.78 | FEN1 (0.50) | FEN1ALOX5APTDO2MAP4K4PIK3CD | |
| SCHEMBL15723953 | 0.76 | FEN1 (0.43) | FEN1ALOX5APMAP4K4PIK3CDMKNK1 | |
| SCHEMBL29889779 | 0.76 | CYP2A6 (0.55) | TDO2CYP11B2MAPT | |
| SCHEMBL22230844 | 0.76 | CYP11B2 (0.47) | CYP11B2MAPTMAOAMAOBMKNK1 | |
| SCHEMBL4512712 | 0.75 | FEN1 (0.55) | FEN1ALOX5APTDO2MAP4K4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981964-B2 | Maleimide derivatives as modulators of wnt pathway | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-29 | — | — | US | disclosed |
| US-9981964-B2 | Maleimide derivatives as modulators of wnt pathway | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-29 | — | — | US | disclosed |
| US-9981964-B2 | Maleimide derivatives as modulators of wnt pathway | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-29 | — | — | US | disclosed |
| EP-3083622-B1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY SCIENCE TECH & RES (SG) | 2018-03-21 | — | — | EP | disclosed |
| EP-3083622-B1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY SCIENCE TECH & RES (SG) | 2018-03-21 | — | — | EP | disclosed |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-03 | — | — | US | disclosed |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-03 | — | — | US | disclosed |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-03 | — | — | US | disclosed |
| EP-3083622-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | Agency For Science, Technology And Research (SG) | 2016-10-26 | — | — | EP | disclosed |
| CN-106061974-A | Maleimide derivatives as modulators of WNT pathway | 新加坡科技研究局 | 2016-10-26 | — | — | CN | disclosed |
| WO-2015187094-A1 | PHTHALIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187094-A1 | PHTHALIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015094118-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094118-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-06-25 | — | — | WO | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009095377-A1 | SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095377-A1 | SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | FEN1 4775/4885ALOX5AP 1069/4885TDO2 1518/4885 |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | WNT1, WNT3, CTNNB1 | FEN1 2876/4885ALOX5AP 4151/4885TDO2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.